SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 31,402 shares, a growth of 407.1% from the July 30th total of 6,193 shares. Based on an average daily trading volume, of 52,642 shares, the days-to-cover ratio is presently 0.6 days.
SAB Biotherapeutics Trading Up 17.3%
Shares of SABSW traded up $0.00 during midday trading on Friday, hitting $0.03. The stock had a trading volume of 4,190 shares, compared to its average volume of 80,269. SAB Biotherapeutics has a 1 year low of $0.00 and a 1 year high of $0.20. The stock’s 50 day moving average is $0.02 and its 200 day moving average is $0.02.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Featured Stories
- Five stocks we like better than SAB Biotherapeutics
- Okta Stock Surges 29%—Is $200 the Next Stop?
- BWX Technologies’ Army Reactor Win Could Redraw Its Nuclear Growth Story
- Meta’s $18 Billion Settlement May Be a Win for Investors
- Intuit’s Earnings Reset May Be More Pivot Than Plunge
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
